Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 2 of 4: Calculated dose-response metrics. - Dataset (ID:20269)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Biological Replicate ID | Conc Unit | GR50 | GEC50 | GRmax | GRinf | GR Hill Coefficient | GR_AOC | GR r2 | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MCF 10F | NM | - | Trastuzumab | HER2 | ErbB | 7487.102 | uM | 5.78510 | 28.60730 | 0.4084 | -1.0000 | 0.6873 | 0.0988 | 0.8554 | 1.5273 | |
| 184B5 | NM | Basal | Trastuzumab | HER2 | ErbB | 9095.026 | uM | inf | 6.71320 | 0.7144 | 0.5130 | 4.9565 | -0.0290 | 0.80 | 1.0168 | |
| MCF 10A | NM | Basal B | Cetuximab | EGFR | ErbB | 7868.018 | uM | inf | inf | 0.9199 | 0.9199 | 0.0000 | -0.0068 | 0.4328 | 2.1110 | |
| HBL-100 | Unknown | Unknown | Pertuzumab | 7429.102 | mg/ml | inf | 0.21142 | 0.9391 | 0.9176 | 0.6095 | 0.0085 | 0.7039 | 2.4347 | |||
| MCF 10A | NM | Basal B | Cetuximab | EGFR | ErbB | 7867.042 | uM | 0.82087 | 0.24212 | 0.5210 | 0.3793 | 1.1638 | 0.0459 | 0.9580 | 2.3427 | |
| HCC1143 | TNBC | Basal A | Cetuximab | EGFR | ErbB | 7809.018 | uM | inf | inf | 0.9659 | 0.9659 | 0.0000 | -0.0257 | -0.2331 | 1.6742 | |
| 184A1 | NM | Basal | Trastuzumab | HER2 | ErbB | 9047.026 | uM | inf | inf | 0.2837 | 0.2837 | 0.0000 | 0.2170 | 0.0804 | 0.5972 | |
| HCC2185 | TNBC | Luminal | Cetuximab | EGFR | ErbB | 7848.042 | uM | inf | inf | 0.8862 | 0.8862 | 0.0000 | -0.0398 | 0.1615 | 0.4157 | |
| MCF7 | HR+ | Luminal | Cetuximab | EGFR | ErbB | 7875.018 | uM | inf | inf | 0.9316 | 0.9316 | 0.0000 | -0.0136 | 0.3967 | 1.6565 | |
| HCC1395 | TNBC | Basal B | Cetuximab | EGFR | ErbB | 7816.042 | uM | inf | inf | 1.0005 | 1.0005 | 0.0000 | -0.0101 | -0.0006 | 0.9332 | |
| HCC1395 | TNBC | Basal B | Cetuximab | EGFR | ErbB | 9258.026 | uM | inf | inf | 0.7953 | 0.7953 | 0.0000 | 0.0354 | 0.3593 | 0.5632 | |
| HCC1395 | TNBC | Basal B | Cetuximab | EGFR | ErbB | 7813.018 | uM | 0.82620 | 0.82952 | 0.7195 | -0.0101 | 4.9982 | 0.0073 | 0.6447 | 0.8420 | |
| HCC1395 | TNBC | Basal B | Cetuximab | EGFR | ErbB | 9254.124 | uM | 1.07170 | 0.71327 | 0.7439 | 0.4322 | 4.9081 | -0.0186 | 0.7673 | 0.8067 | |
| HCC1395 | TNBC | Basal B | Cetuximab | EGFR | ErbB | 7814.042 | uM | 1.1580 | 1.97410 | 0.7528 | -0.7381 | 1.6997 | 0.0120 | 0.7787 | 0.8414 | |
| MDA-MB-361 | HER2amp | Luminal | Cetuximab | EGFR | ErbB | 7895.018 | uM | inf | inf | 0.9756 | 0.9756 | 0.0000 | 0.0240 | -0.0375 | 1.2916 | |
| MDA-MB-361 | HER2amp | Luminal | Cetuximab | EGFR | ErbB | 7896.042 | uM | inf | inf | 0.9737 | 0.9737 | 0.0000 | -0.0276 | -0.7203 | 1.1632 | |
| BT-474 | HER2amp | Luminal | Trastuzumab | HER2 | ErbB | 9158.123 | uM | 0.01277 | 0.00885 | -0.0100 | 0.0993 | 0.6043 | 0.4533 | 0.9046 | 0.8769 | |
| BT-474 | HER2amp | Luminal | Trastuzumab | HER2 | ErbB | 9163.026 | uM | 0.00135 | 0.0020 | -0.6688 | -0.4240 | 1.5559 | 0.8993 | 0.9648 | 0.3738 | |
| MDA-MB-361 | HER2amp | Luminal | Cetuximab | EGFR | ErbB | 9648.026 | uM | inf | inf | 0.9880 | 0.9880 | 0.0000 | -0.0302 | -1.2808 | 0.7065 | |
| HCC1143 | TNBC | Basal A | Cetuximab | EGFR | ErbB | 9233.124 | uM | 0.71405 | 0.79473 | 0.5278 | -0.1473 | 2.4126 | 0.0082 | 0.9191 | 0.9990 | |
| HCC1143 | TNBC | Basal A | Cetuximab | EGFR | ErbB | 7810.006 | uM | inf | inf | 0.8576 | 0.8576 | 0.0000 | 0.0064 | 0.5591 | 0.9730 | |
| MDA-MB-157 | TNBC | Basal B | Cetuximab | EGFR | ErbB | 7879.018 | uM | inf | inf | 0.9952 | 0.9952 | 0.0000 | -0.0245 | -1.0109 | 1.7910 | |
| HCC2185 | TNBC | Luminal | Cetuximab | EGFR | ErbB | 7845.018 | uM | inf | inf | 0.3134 | 0.3134 | 0.0000 | 0.1983 | 0.0987 | 0.4518 |